Literature DB >> 33263382

Corrigendum.

.   

Abstract

Year:  2020        PMID: 33263382      PMCID: PMC8097606          DOI: 10.1111/apt.16079

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


× No keyword cloud information.
  1 in total

1.  Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.

Authors:  Matthew Bohm; Ronghui Xu; Yiran Zhang; Sashidhar Varma; Monika Fischer; Gursimran Kochhar; Brigid Boland; Siddharth Singh; Robert Hirten; Ryan Ungaro; Eugenia Shmidt; Karen Lasch; Vipul Jairaith; David Hudesman; Shannon Chang; Dana Lukin; Arun Swaminath; Bruce E Sands; Jean-Frederic Colombel; Sunanda Kane; Edward V Loftus; Bo Shen; Corey A Siegel; William J Sandborn; Parambir S Dulai
Journal:  Aliment Pharmacol Ther       Date:  2020-07-13       Impact factor: 9.524

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.